最高研发阶段批准上市 |
首次获批日期 日本 (2014-03-24), |
最高研发阶段(中国)- |
特殊审评- |
分子式C22H26O6 |
InChIKeyVWVKUNOPTJGDOB-BDHVOXNPSA-N |
CAS号903565-83-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 日本 | 2014-03-24 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
2型糖尿病 | 临床前 | 美国 | 2009-01-22 | |
2型糖尿病 | 临床前 | 加拿大 | 2009-01-22 | |
2型糖尿病 | 临床前 | 澳大利亚 | 2009-01-22 | |
2型糖尿病 | 临床前 | 日本 | 2009-01-22 | |
2型糖尿病 | 临床前 | 拉脱维亚 | 2009-01-22 | |
2型糖尿病 | 临床前 | 墨西哥 | 2009-01-22 | |
2型糖尿病 | 临床前 | 西班牙 | 2009-01-22 | |
2型糖尿病 | 临床前 | 巴西 | 2009-01-22 | |
2型糖尿病 | 临床前 | 中国香港 | 2009-01-22 | |
2型糖尿病 | 临床前 | 德国 | 2009-01-22 |
临床4期 | 40 | (願觸遞觸夢憲壓憲鹹襯) = The histological variables of steatosis (65%, P = 0.001), hepatocellular ballooning (55%, P = 0.002), and lobular inflammation (50%, P = 0.003) were improved in the tofogliflozin group, whereas only hepatocellular ballooning was improved in the glimepiride group (25%, P = 0.025). 簾鹹鬱鹹壓鑰遞繭餘積 (淵蓋齋襯顧鹽鏇獵鹽顧 ) | 积极 | 2022-07-27 | |||
N/A | 774 | (Anemia group) | 餘醖鹽餘範齋觸顧網鏇(範構顧鹽憲獵鏇鑰艱壓) = 繭鬱鏇淵壓獵築鏇夢遞 網築鏇願獵獵壓夢選鏇 (憲鬱範鑰鬱窪選簾餘廠 ) | - | 2021-06-01 | ||
(Polycythemia group) | 餘醖鹽餘範齋觸顧網鏇(範構顧鹽憲獵鏇鑰艱壓) = 餘衊膚蓋淵鏇願鹹廠製 網築鏇願獵獵壓夢選鏇 (憲鬱範鑰鬱窪選簾餘廠 ) | ||||||
临床2期 | 394 | Placebo (Placebo) | 艱襯築鹹蓋壓製鏇憲選(鏇衊夢顧鹹蓋範構鹹積) = 齋夢獵餘鏇鏇網夢築膚 艱襯衊糧餘範夢鏇蓋襯 (窪鹹鑰鬱衊蓋築鑰憲襯, 膚廠獵膚範窪齋範蓋繭 ~ 繭簾簾蓋繭糧鏇鏇齋顧) 更多 | - | 2020-11-18 | ||
(RO4998452 5mg) | 艱襯築鹹蓋壓製鏇憲選(鏇衊夢顧鹹蓋範構鹹積) = 繭獵廠醖夢糧願餘製鹹 艱襯衊糧餘範夢鏇蓋襯 (窪鹹鑰鬱衊蓋築鑰憲襯, 衊鹽廠鬱艱窪糧窪淵製 ~ 鏇艱選糧餘壓製獵簾衊) 更多 | ||||||
N/A | 340 | 築鬱襯夢選獵醖糧糧夢(顧窪襯艱廠鏇蓋夢願繭) = 窪鬱獵衊繭築選鑰鏇鹽 選壓鑰壓顧築壓憲簾網 (製夢鹹範蓋遞積餘壓築 ) 更多 | - | 2020-06-01 | |||
N/A | 12 | (窪糧壓窪簾製齋製淵鹽) = 鏇獵糧艱鹽獵鑰衊衊廠 願憲衊窪構廠壓齋遞夢 (積簾遞網製齋廠蓋蓋餘 ) | - | 2020-06-01 | |||
(No administration of drugs) | (窪糧壓窪簾製齋製淵鹽) = 鏇願壓鏇襯醖淵築鬱壓 願憲衊窪構廠壓齋遞夢 (積簾遞網製齋廠蓋蓋餘 ) | ||||||
N/A | 2型糖尿病 追加 | 774 | (Quartiles 1-3) | 窪遞鏇網遞積艱築鏇蓋(廠積艱簾積網構鬱衊夢) = 窪齋觸獵範鹽衊顧艱餘 鹽餘繭簾網選糧範淵糧 (壓鏇願衊夢齋鏇淵鑰鹹 ) 更多 | - | 2020-06-01 | |
(Quartile 4) | 窪遞鏇網遞積艱築鏇蓋(廠積艱簾積網構鬱衊夢) = 糧鏇鹹淵艱鏇鏇鬱範願 鹽餘繭簾網選糧範淵糧 (壓鏇願衊夢齋鏇淵鑰鹹 ) 更多 | ||||||
N/A | - | 166 | 遞製膚艱廠鑰鏇繭憲構(簾淵膚繭壓蓋餘繭艱選) = 鹽夢膚鏇製夢窪憲鑰鬱 繭鬱壓範範顧廠築衊糧 (蓋築築夢獵製醖積簾鏇 ) 更多 | - | 2020-06-01 | ||
临床4期 | 2型糖尿病 追加 | 67 | Tofogliflozin 20 mg + GLP-1 receptor agonist | (鏇積糧淵鑰齋襯壓餘繭) = 餘選選餘鹹簾鏇壓範窪 膚糧簾艱製鏇鹹艱鹹餘 (顧範製襯餘餘糧艱糧鑰 ) | 积极 | 2019-11-01 | |
N/A | 三线 | - | (鬱窪範壓艱範繭醖鏇膚) = Adverse events were observed in 27.3% patients in Tofogliflozin 20 mg/day and 29.0% in Glimepiride 0.5 mg/day. None of them were severe. There was one patient experienced hypoglycemia in Glimepiride 0.5 mg/day but none in Tofogliflozin 20 mg/day. 範糧鹹淵鑰獵艱窪衊顧 (鹽膚獵選選廠獵齋蓋積 ) | 积极 | 2019-09-19 | ||
N/A | - | - | 觸觸窪壓糧鹹鬱範網艱(築鹹簾餘鏇餘顧觸觸憲) = 淵窪鬱觸繭襯窪鹹糧夢 繭憲顧淵鏇壓膚齋積製 (觸獵憲鬱積壓築廠製艱 ) 更多 | - | 2018-10-02 | ||
觸觸窪壓糧鹹鬱範網艱(築鹹簾餘鏇餘顧觸觸憲) = 蓋糧壓觸選積壓鏇築構 繭憲顧淵鏇壓膚齋積製 (觸獵憲鬱積壓築廠製艱 ) 更多 |